Potential for antihypertensive treatment with an AT1-receptor blocker to reduce dementia in the elderly

Journal of Human Hypertension

Volumn 16, Issue , 2002, Pages S71-S75

  Trenkwalder, P ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Candesartan; Cognitive function; Dementia; Elderly; Scope

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTIINFLAMMATORY AGENT; ANTILIPEMIC AGENT; CANDESARTAN HEXETIL; HYDROCHLOROTHIAZIDE; LOSARTAN; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO;

AGED; ALZHEIMER DISEASE; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMENTIA; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; EPIDEMIOLOGICAL DATA; GERIATRIC DISORDER; HUMAN; HYPERTENSION; HYPERURICEMIA; HYPOKALEMIA; LONG TERM CARE; MORBIDITY; MORTALITY; RANDOMIZED CONTROLLED TRIAL; STROKE; WHITE MATTER;

AGED; AGING; ANTIHYPERTENSIVE AGENTS; COGNITION; DEMENTIA; HUMANS; MODELS, NEUROLOGICAL; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTORS, ANGIOTENSIN;

EID: 0036670378     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/sj.jhh.1001443     Document Type: Article

References (24)

1. Kannel WB, Gordon T, Evaluation of cardiovascular risk in the elderly: the Framingham Study. Bull NY Acad Med 1978; 54: 573-591.
2. Joint National Committee. Sixth National Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC VI). Arch Intern Med 1997; 157: 2413-2446.
3. Staessen JA Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analy- sis of outcome trials. Lancet 2000; 355: 865-872.
4. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 3rd edition, revised. American Psychiatric Association: Washington DC, 1987.
5. Jorm AF, Korten AE, Henderson AS. The prevalence of dementia: a quantitative integration of the literature. Acta Psychiatr Scand 1987; 76: 465-479.
6. Tzourio C, Anderson C, PROGRESS Management Committee. Blood pressure reduction and risk of dementia in patients with stroke: rationale of the dementia assessment in PROGRESS (Perindopril Protection against Recurrent Stroke Study). PROGRESS Management Committee. Hypertens 2000; 18 (Suppl): S21- 24.
7. Hofman A Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer’s disease in the Rotterdam Study. Lancet 1997; 349: 151-154.
8. Snowdon DA Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA 1997; 278: 113-114.
9. Elias MF Untreated blood pressure level is inversely related to cognitive functioning: the Framingham Study. Am J Epidemiol 1993; 138: 353-364.
10. Launer LJ The association between midlife blood pressure levels and late-life cognitive function. The Honolulu-Asia Aging Study. JAMA 1995; 274: 1846- 1851.
11. Skoog I 15-year longitudinal study of blood pressure and dementia. Lancet 1996; 347: 1141-1145.
12. Scheinberg P. Dementia due to vascular disease: a multifactorial disorder. Stroke 1988; 19: 1291-1299.
13. Román GC. Senile dementia of the Binswanger type: a vascular form of dementia in the elderly. JAMA 1987; 258:1782-1788.
14. Brun A, Englund E. A white matter disorder in dementia of the Alzheimer type: a pathoanatomical study. Ann Neurol 1986; 19: 253-262.
15. Trenkwalder P et al. Prevalence, awareness, treatment and control of hypertension in a population over the age of 65 years: results from the Starnberg Study on Epidemiology of Parkinsonism and Hypertension in the Elderly Hypertens 1994; 12: 709 -716.
16. Forette F Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 1998; 352: 1347-1351.
17. Tedesco MA Comparison of losartan and hydrochlorothiazide on cognitive function and quality of life in hypertensive patients. Am J Hypertens 1999; 12 (11 Pt 12): 1130-1134.
18. Hansson L Study on COgnition and Prognosis in the Elderly (SCOPE). Blood Press 1999; 8: 177-183.
19. Hansson L Study on COgnition and Prognosis in the Elderly (SCOPE): baseline characteristics. Blood Press 2000; 9: 146-151.
20. Elmfeldt D, George M, Hüber R, Olofsson B. Candesar- tan cilexetil, a new generation angiotensin II antagonist, provides dose dependent antihypertensive effect.Hum Hypertens 1997; 11 (Suppl 2): S49-S53.
21. Mclnnes GT, O’Kane KPJ, Jonker J, Roth J. The efficacy and tolerability of candesartan cilexetil in an elderly hypertensive population. Hum Hypertens 1997; 11 (Suppl 2): S75-S80.
22. Neldam S, Forsen B, for the Multicentre Study Group. Antihypertensive treatment in elderly patients aged 75 years or over: a 24-week study of the tolerability of candesartan cilexetil in relation to hydrochlorothiazide. Drugs Aging 2001; 18: 225-232.
23. n) receptor blockade in hypertensive women: benefits of candesartan cilexetil versus enalapril or hydrochlorothiazide. Am J Hypertens 2000; 13; 504- 511.
24. Belcher G Safety and tolerability of candesartan cilexetil in the elderly. JHypertens 1998; 16 (Suppl 2): 249.